Home LiteratureArticle Details
PMID: 24457416 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge.

Nature reviews. Cancer ·Vol. 14 ·No. 2 ·2014-02-00 ·Pages 92-107

Sturm D, Bender S, Jones DT, Lichter P, Grill J, Becher O, Hawkins C, Majewski J, Jones C, Costello JF, Iavarone A, Aldape K, Brennan CW, Jabado N, Pfister SM

Abstract

We have extended our understanding of the molecular biology that underlies adult glioblastoma over many years. By contrast, high-grade gliomas in children and adolescents have remained a relatively under-investigated disease. The latest large-scale genomic and epigenomic profiling studies have yielded an unprecedented abundance of novel data and provided deeper insights into gliomagenesis across all age groups, which has highlighted key distinctions but also some commonalities. As we are on the verge of dissecting glioblastomas into meaningful biological subgroups, this Review summarizes the hallmark genetic alterations that are associated with distinct epigenetic features and patient characteristics in both paediatric and adult disease, and examines the complex interplay between the glioblastoma genome and epigenome.

MeSH Terms
Age Factors Epigenomics Glioblastoma/genetics Humans Neoplasms, Nerve Tissue/genetics
Authors & Affiliations
15 authors, click to expand affiliations / ORCID
Sturm Dominik
1] Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) Heidelberg, Im Neuenheimer Feld 580, D-69120 Heidelberg, Germany. [2] Department of Pediatric Oncology, Hematology, and Immunology, Heidelberg University Hospital, Im Neuenheimer Feld 430, D-69120 Heidelberg, Germany. [3].
Bender Sebastian
1] Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) Heidelberg, Im Neuenheimer Feld 580, D-69120 Heidelberg, Germany. [2] Department of Pediatric Oncology, Hematology, and Immunology, Heidelberg University Hospital, Im Neuenheimer Feld 430, D-69120 Heidelberg, Germany. [3].
Jones David T W
Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) Heidelberg, Im Neuenheimer Feld 580, D-69120 Heidelberg, Germany.
Lichter Peter
Division of Molecular Genetics, German Cancer Research Center (DKFZ) Heidelberg, Im Neuenheimer Feld 580, D-69120 Heidelberg, Germany.
Grill Jacques
Brain Tumor Program, Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Institute, Université Paris-Sud, 114 Rue Eduoard Vaillant, 94805 Villejuif, France.
Becher Oren
Division of Pediatric Hematology-Oncology, Duke University Medical Center, DUMC 91001, Durham, North Carolina 27710, USA.
Hawkins Cynthia
The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, M5G 1X8, Canada.
Majewski Jacek
Division of Experimental Medicine and Department of Human Genetics, McGill University and McGill University Health Centre, 2155 Guy Street, Montreal, Québec, H3H 2R9, Canada.
Jones Chris
Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.
Costello Joseph F
Brain Tumor Research Center, Department of Neurosurgery, University of California, 2340 Sutter Street, San Francisco, California 94143, USA.
Iavarone Antonio
Institute for Cancer Genetics and Departments of Pathology and Neurology, Columbia University Medical Center, 1130 St. Nicholas Avenue, New York, New York 10032, USA.
Aldape Kenneth
Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0085, Houston, Texas 77030, USA.
Brennan Cameron W
Human Oncology & Pathogenesis Program and Department of Neurosurgery, Brain Tumor Center, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, New York 10065, USA.
Jabado Nada
Division of Experimental Medicine and Department of Human Genetics, McGill University and McGill University Health Centre, 2155 Guy Street, Montreal, Québec, H3H 2R9, Canada.
Pfister Stefan M
1] Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) Heidelberg, Im Neuenheimer Feld 580, D-69120 Heidelberg, Germany. [2] Department of Pediatric Oncology, Hematology, and Immunology, Heidelberg University Hospital, Im Neuenheimer Feld 430, D-69120 Heidelberg, Germany.
References (223)
223 references, click to expand
  1. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities.
    Cancer Res. 2006 Dec 1;66(23):11502-13 PMID: 17114236
  2. Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology.
    Cancer Treat Rev. 2012 Feb;38(1):27-35 PMID: 21764221
  3. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression.
    Genes Dev. 2013 May 1;27(9):985-90 PMID: 23603901
  4. Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma.
    Proc Natl Acad Sci U S A. 2011 Mar 15;108(11):4453-8 PMID: 21368213
  5. Expression of the oligodendroglial lineage-associated markers Olig1 and Olig2 in different types of human gliomas.
    J Neuropathol Exp Neurol. 2003 Oct;62(10):1052-9 PMID: 14575240
  6. Incidence of gliomas by anatomic location.
    Neuro Oncol. 2007 Jul;9(3):319-25 PMID: 17522333
  7. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice.
    Science. 2012 Nov 23;338(6110):1080-4 PMID: 23087000
  8. Transforming fusions of FGFR and TACC genes in human glioblastoma.
    Science. 2012 Sep 7;337(6099):1231-5 PMID: 22837387
  9. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia.
    Cancer Res. 1999 Feb 15;59(4):793-7 PMID: 10029064
  10. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
    J Clin Oncol. 2009 Oct 1;27(28):4733-40 PMID: 19720927
  11. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.
    Cancer Cell. 2011 Dec 13;20(6):810-7 PMID: 22137795
  12. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas.
    PLoS One. 2011;6(12):e28585 PMID: 22194861
  13. Cancer epigenetics: from mechanism to therapy.
    Cell. 2012 Jul 6;150(1):12-27 PMID: 22770212
  14. Combinations of genetic mutations in the adult neural stem cell compartment determine brain tumour phenotypes.
    EMBO J. 2010 Jan 6;29(1):222-35 PMID: 19927122
  15. Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas.
    Cancer Res. 2013 Oct 15;73(20):6219-29 PMID: 23970477
  16. Spatio-temporal transcriptome of the human brain.
    Nature. 2011 Oct 26;478(7370):483-9 PMID: 22031440
  17. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Br J Cancer. 2007 Apr 10;96(7):1047-51 PMID: 17353924
  18. Double minute chromosomes in glioblastoma multiforme are revealed by precise reconstruction of oncogenic amplicons.
    Cancer Res. 2013 Oct 1;73(19):6036-45 PMID: 23940299
  19. Cancer stem cells.
    N Engl J Med. 2006 Sep 21;355(12):1253-61 PMID: 16990388
  20. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes.
    Cancer Res. 2003 Oct 15;63(20):6613-25 PMID: 14583454
  21. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
    Science. 2007 Oct 12;318(5848):287-90 PMID: 17872411
  22. Intratumoral patterns of genomic imbalance in glioblastomas.
    Brain Pathol. 2010 Sep;20(5):936-44 PMID: 20406234
  23. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.
    Genes Dev. 2010 Aug 15;24(16):1731-45 PMID: 20713517
  24. Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis.
    Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2712-6 PMID: 19196966
  25. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.
    Acta Neuropathol. 2013 Dec;126(6):907-15 PMID: 24154961
  26. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.
    Cancer Cell. 2006 May;9(5):391-403 PMID: 16697959
  27. Targeting MYCN in neuroblastoma by BET bromodomain inhibition.
    Cancer Discov. 2013 Mar;3(3):308-23 PMID: 23430699
  28. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
    Clin Cancer Res. 2013 Sep 15;19(18):5146-57 PMID: 23918605
  29. Gene expression profiling of gliomas strongly predicts survival.
    Cancer Res. 2004 Sep 15;64(18):6503-10 PMID: 15374961
  30. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas.
    Nat Genet. 2013 Jun;45(6):602-12 PMID: 23583981
  31. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
    Cancer Cell. 2010 Jan 19;17(1):98-110 PMID: 20129251
  32. Tumor heterogeneity: causes and consequences.
    Biochim Biophys Acta. 2010 Jan;1805(1):105-17 PMID: 19931353
  33. Asymmetry-defective oligodendrocyte progenitors are glioma precursors.
    Cancer Cell. 2011 Sep 13;20(3):328-40 PMID: 21907924
  34. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
    J Clin Oncol. 2009 Feb 1;27(4):579-84 PMID: 19075262
  35. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma.
    Science. 2013 May 17;340(6134):857-61 PMID: 23539183
  36. Feasibility, safety, and indications for surgical biopsy of intrinsic brainstem tumors in children.
    Childs Nerv Syst. 2013 Aug;29(8):1313-9 PMID: 23666401
  37. A distinct spectrum of copy number aberrations in pediatric high-grade gliomas.
    Clin Cancer Res. 2010 Jul 1;16(13):3368-77 PMID: 20570930
  38. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
    Cancer Cell. 2010 May 18;17(5):510-22 PMID: 20399149
  39. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
    N Engl J Med. 2000 Nov 9;343(19):1350-4 PMID: 11070098
  40. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort.
    Cancer Res. 2001 Oct 15;61(20):7404-7 PMID: 11606370
  41. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered.
    FEBS J. 2013 Nov;280(21):5350-70 PMID: 23777544
  42. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.
    Nat Genet. 2013 Aug;45(8):927-32 PMID: 23817572
  43. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.
    J Neurooncol. 2010 Feb;96(3):393-402 PMID: 19688297
  44. The transcriptional network for mesenchymal transformation of brain tumours.
    Nature. 2010 Jan 21;463(7279):318-25 PMID: 20032975
  45. A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival.
    Genes Dev. 2013 Jul 1;27(13):1462-72 PMID: 23796897
  46. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
    Cancer Cell. 2010 Mar 16;17(3):225-34 PMID: 20171147
  47. The integrated landscape of driver genomic alterations in glioblastoma.
    Nat Genet. 2013 Oct;45(10):1141-9 PMID: 23917401
  48. Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma: a matched-cohort analysis.
    Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):315-20 PMID: 22682807
  49. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis.
    Cell. 2012 Aug 17;150(4):685-96 PMID: 22901803
  50. Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays.
    Acta Neuropathol. 2013 Jun;125(6):913-6 PMID: 23670100
  51. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
    Neuro Oncol. 2013 Sep;15(9):1114-26 PMID: 23877318
  52. Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma.
    Cancer Cell. 2012 Jan 17;21(1):11-24 PMID: 22264785
  53. An integrated genomic analysis of human glioblastoma multiforme.
    Science. 2008 Sep 26;321(5897):1807-12 PMID: 18772396
  54. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC.
    Cancer Cell. 2012 May 15;21(5):601-613 PMID: 22624711
  55. MGMT gene silencing and benefit from temozolomide in glioblastoma.
    N Engl J Med. 2005 Mar 10;352(10):997-1003 PMID: 15758010
  56. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations.
    Acta Neuropathol. 2012 Nov;124(5):615-25 PMID: 22886134
  57. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme.
    Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5814-9 PMID: 15827123
  58. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.
    Clin Cancer Res. 2009 Sep 15;15(18):5753-61 PMID: 19737945
  59. Gene expression profiling identifies molecular subtypes of gliomas.
    Oncogene. 2003 Jul 31;22(31):4918-23 PMID: 12894235
  60. The definition of primary and secondary glioblastoma.
    Clin Cancer Res. 2013 Feb 15;19(4):764-72 PMID: 23209033
  61. Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN.
    Cancer Discov. 2013 May;3(5):512-9 PMID: 23539269
  62. Distinct transcription profiles of primary and secondary glioblastoma subgroups.
    Cancer Res. 2006 Jan 1;66(1):159-67 PMID: 16397228
  63. MGMT gene promoter methylation in pediatric glioblastomas.
    Childs Nerv Syst. 2010 Nov;26(11):1613-8 PMID: 20585787
  64. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
    Lancet Oncol. 2012 Sep;13(9):916-26 PMID: 22877848
  65. Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis.
    Clin Cancer Res. 2007 Dec 15;13(24):7341-56 PMID: 18094416
  66. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas.
    Brain Pathol. 2004 Apr;14(2):131-6 PMID: 15193025
  67. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
    Acta Neuropathol. 2013 Aug;126(2):267-76 PMID: 23764841
  68. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth.
    Clin Cancer Res. 2010 Jan 1;16(1):154-63 PMID: 20048334
  69. Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors.
    Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10851-6 PMID: 11526205
  70. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
    Int J Cancer. 2011 Aug 1;129(3):659-70 PMID: 21425258
  71. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases.
    EMBO Rep. 2011 May;12(5):463-9 PMID: 21460794
  72. Epigenetic silencing of the protocadherin family member PCDH-gamma-A11 in astrocytomas.
    Neoplasia. 2005 Mar;7(3):193-9 PMID: 15799819
  73. A mouse model for glioma: biology, pathology, and therapeutic opportunities.
    Toxicol Pathol. 2000 Jan-Feb;28(1):171-7 PMID: 10669005
  74. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.
    J Clin Oncol. 2011 Jan 10;29(2):142-8 PMID: 21135282
  75. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
    J Clin Oncol. 2013 Sep 10;31(26):3212-8 PMID: 23940216
  76. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets.
    J Clin Oncol. 2010 Mar 10;28(8):1337-44 PMID: 20142589
  77. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.
    Proc Natl Acad Sci U S A. 2010 Dec 7;107(49):20980-5 PMID: 21078963
  78. Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors.
    J Neuropathol Exp Neurol. 2007 Oct;66(10):944-54 PMID: 17917588
  79. Telomerase activity and hTERT mRNA expression in glial tumors.
    Int J Oncol. 2006 Jun;28(6):1555-60 PMID: 16685456
  80. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology.
    Cancer Res. 2009 Dec 1;69(23):9065-72 PMID: 19920198
  81. Genetically engineered models have advantages over xenografts for preclinical studies.
    Cancer Res. 2006 Apr 1;66(7):3355-8, discussion 3358-9 PMID: 16585152
  82. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1.
    Nat Med. 2013 Jul;19(7):901-908 PMID: 23793099
  83. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.
    Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3041-6 PMID: 22323597
  84. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSα.
    Cell. 2013 Apr 25;153(3):590-600 PMID: 23622243
  85. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model.
    Cancer Cell. 2009 Jan 6;15(1):45-56 PMID: 19111880
  86. Pten haploinsufficiency accelerates formation of high-grade astrocytomas.
    Cancer Res. 2008 May 1;68(9):3286-94 PMID: 18451155
  87. Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity.
    Cancer Res. 2012 Apr 1;72(7):1614-20 PMID: 22311673
  88. Genetic determinants of malignancy in a mouse model for oligodendroglioma.
    Cancer Res. 2003 Apr 1;63(7):1589-95 PMID: 12670909
  89. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
    Lancet Oncol. 2009 May;10(5):459-66 PMID: 19269895
  90. Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects.
    Proc Natl Acad Sci U S A. 2004 Aug 31;101(35):13008-13 PMID: 15319471
  91. Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma.
    Cancer Res. 2006 Jul 1;66(13):6473-6 PMID: 16818615
  92. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma.
    J Clin Oncol. 2011 Oct 20;29(30):3999-4006 PMID: 21931021
  93. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
    Nature. 2009 Dec 10;462(7274):739-44 PMID: 19935646
  94. Diffuse brainstem glioma in children: critical review of clinical trials.
    Lancet Oncol. 2006 Mar;7(3):241-8 PMID: 16510333
  95. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations.
    Clin Cancer Res. 1999 Dec;5(12):4085-90 PMID: 10632344
  96. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).
    Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2989-94 PMID: 22323599
  97. Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.
    Nat Commun. 2013;4:2166 PMID: 23863747
  98. IDH mutations in human glioma.
    Neurosurg Clin N Am. 2012 Jul;23(3):471-80 PMID: 22748659
  99. Genetic pathways to primary and secondary glioblastoma.
    Am J Pathol. 2007 May;170(5):1445-53 PMID: 17456751
  100. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.
    Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4009-14 PMID: 23412337
  101. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma.
    Br J Cancer. 2009 Dec 15;101(12):1995-2004 PMID: 19904263
  102. Intratumoral cytogenetic heterogeneity detected by comparative genomic hybridization and laser scanning cytometry in human gliomas.
    Cancer Res. 1998 Oct 15;58(20):4694-700 PMID: 9788624
  103. RHPN2 drives mesenchymal transformation in malignant glioma by triggering RhoA activation.
    Cancer Res. 2013 Aug 15;73(16):5140-50 PMID: 23774217
  104. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors.
    J Clin Oncol. 2007 Apr 1;25(10):1196-208 PMID: 17401009
  105. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas.
    Nat Genet. 2012 Jan 29;44(3):251-3 PMID: 22286216
  106. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.
    Cancer Cell. 2012 Oct 16;22(4):425-37 PMID: 23079654
  107. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
    Science. 2013 May 3;340(6132):626-30 PMID: 23558169
  108. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.
    J Neurooncol. 2012 Mar;107(1):133-8 PMID: 21984064
  109. High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model.
    Cancer Res. 2006 Aug 1;66(15):7429-37 PMID: 16885338
  110. Molecular structure of double-minute chromosomes bearing amplified copies of the epidermal growth factor receptor gene in gliomas.
    Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11368-73 PMID: 15269346
  111. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
    Lancet Oncol. 2012 Jul;13(7):707-15 PMID: 22578793
  112. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
    Cancer Cell. 2010 Dec 14;18(6):553-67 PMID: 21130701
  113. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas.
    Genes Dev. 2010 Oct 1;24(19):2205-18 PMID: 20889717
  114. Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model.
    Cancer Res. 2003 Mar 1;63(5):1106-13 PMID: 12615729
  115. MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA.
    Childs Nerv Syst. 2011 Nov;27(11):1877-83 PMID: 21789683
  116. OLIG2 as a specific marker of oligodendroglial tumour cells.
    Lancet. 2001 Jul 28;358(9278):298-300 PMID: 11498220
  117. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation.
    Cancer Res. 1996 May 15;56(10):2405-10 PMID: 8625319
  118. The Pediatric Cancer Genome Project.
    Nat Genet. 2012 May 29;44(6):619-22 PMID: 22641210
  119. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.
    Neuro Oncol. 2012 Feb;14(2):215-21 PMID: 22090453
  120. Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma.
    Cancer Cell. 2013 Sep 9;24(3):331-46 PMID: 23993863
  121. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice.
    Genes Dev. 1998 Dec 1;12(23):3675-85 PMID: 9851974
  122. Molecular subclassification of diffuse gliomas: seeing order in the chaos.
    Glia. 2011 Aug;59(8):1190-9 PMID: 21446051
  123. Age-specific signatures of glioblastoma at the genomic, genetic, and epigenetic levels.
    PLoS One. 2013 Apr 29;8(4):e62982 PMID: 23658659
  124. Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain.
    Cancer Cell. 2011 Mar 8;19(3):305-16 PMID: 21397855
  125. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma.
    Ann Oncol. 2009 Sep;20(9):1596-1603 PMID: 19491283
  126. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.
    Cancer Res. 2010 Jan 15;70(2):512-9 PMID: 20068183
  127. The somatic genomic landscape of glioblastoma.
    Cell. 2013 Oct 10;155(2):462-77 PMID: 24120142
  128. Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis.
    J Neurooncol. 2011 Nov;105(2):325-35 PMID: 21523485
  129. EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma.
    Cancer Res. 2005 Apr 1;65(7):2565-71 PMID: 15805250
  130. Paediatric and adult malignant glioma: close relatives or distant cousins?
    Nat Rev Clin Oncol. 2012 May 29;9(7):400-13 PMID: 22641364
  131. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.
    Cancer Cell. 2007 Feb;11(2):147-60 PMID: 17292826
  132. Gene expression profiling from formalin-fixed paraffin-embedded tumors of pediatric glioblastoma.
    Clin Cancer Res. 2007 Nov 1;13(21):6284-92 PMID: 17975139
  133. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme.
    Mol Cancer Res. 2006 Oct;4(10):709-14 PMID: 17050665
  134. Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas.
    Neuro Oncol. 2010 Feb;12(2):153-63 PMID: 20150382
  135. Chromatin remodeling defects in pediatric and young adult glioblastoma: a tale of a variant histone 3 tail.
    Brain Pathol. 2013 Mar;23(2):210-6 PMID: 23432647
  136. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.
    Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):14164-9 PMID: 22891331
  137. Mosaic analysis with double markers reveals tumor cell of origin in glioma.
    Cell. 2011 Jul 22;146(2):209-21 PMID: 21737130
  138. Evidence of focal genetic microheterogeneity in glioblastoma multiforme by area-specific CGH on microdissected tumor cells.
    J Neuropathol Exp Neurol. 1999 Sep;58(9):993-9 PMID: 10499441
  139. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease.
    J Clin Oncol. 2010 Jun 20;28(18):3061-8 PMID: 20479398
  140. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma.
    Brain Pathol. 2013 Sep;23(5):565-73 PMID: 23438035
  141. Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation.
    Cancer Res. 2006 Sep 1;66(17):8469-76 PMID: 16951158
  142. Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation.
    Mol Cell Biol. 2002 Jul;22(14):5100-13 PMID: 12077339
  143. TP53 promoter methylation in human gliomas.
    Acta Neuropathol. 2005 Aug;110(2):178-84 PMID: 16025287
  144. Methylation-related chromatin structure is associated with exclusion of transcription factors from and suppressed expression of the O-6-methylguanine DNA methyltransferase gene in human glioma cell lines.
    Mol Cell Biol. 1994 Oct;14(10):6515-21 PMID: 7523853
  145. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect.
    Nat Cell Biol. 2012 Dec;14(12):1295-304 PMID: 23178880
  146. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial.
    Mol Cancer Ther. 2011 Jun;10(6):1102-12 PMID: 21471286
  147. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.
    J Clin Oncol. 2008 Oct 1;26(28):4659-65 PMID: 18824712
  148. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.
    J Clin Invest. 2013 Feb;123(2):855-65 PMID: 23298836
  149. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
    Nature. 2012 Feb 15;483(7390):479-83 PMID: 22343889
  150. Valproic acid use during radiation therapy for glioblastoma associated with improved survival.
    Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):504-9 PMID: 23523186
  151. GFAP promoter driven transgenic expression of PDGFB in the mouse brain leads to glioblastoma in a Trp53 null background.
    Glia. 2009 Aug 15;57(11):1143-53 PMID: 19115382
  152. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.
    Clin Cancer Res. 2009 Jul 15;15(14):4622-9 PMID: 19584161
  153. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification.
    Cancer Res. 2003 Apr 1;63(7):1602-7 PMID: 12670911
  154. Diffuse intrinsic pontine glioma: poised for progress.
    Front Oncol. 2012 Dec 28;2:205 PMID: 23293772
  155. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
    Cancer Cell. 2011 Jan 18;19(1):17-30 PMID: 21251613
  156. Inhibition of EGFR induces a c-MET-driven stem cell population in glioblastoma.
    Stem Cells. 2014 Feb;32(2):338-48 PMID: 24115218
  157. Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β.
    Mol Cancer Ther. 2011 Aug;10(8):1407-18 PMID: 21659463
  158. Altered telomeres in tumors with ATRX and DAXX mutations.
    Science. 2011 Jul 22;333(6041):425 PMID: 21719641
  159. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects.
    Nat Genet. 2000 Sep;26(1):109-13 PMID: 10973261
  160. Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas.
    PLoS One. 2012;7(2):e30313 PMID: 22389665
  161. Transposon mutagenesis identifies genes that transform neural stem cells into glioma-initiating cells.
    Proc Natl Acad Sci U S A. 2012 Oct 30;109(44):E2998-3007 PMID: 23045694
  162. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Pediatr Blood Cancer. 2007 Apr;48(4):403-7 PMID: 16609952
  163. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
    Clin Cancer Res. 2006 Aug 15;12(16):4899-907 PMID: 16914578
  164. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function.
    Genes Dev. 2012 Sep 15;26(18):2038-49 PMID: 22925884
  165. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
    Neurology. 2011 Sep 20;77(12):1156-64 PMID: 21880994
  166. Interplay between the cancer genome and epigenome.
    Cell. 2013 Mar 28;153(1):38-55 PMID: 23540689
  167. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.
    J Clin Oncol. 2011 Dec 1;29(34):4482-90 PMID: 22025148
  168. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma.
    Genes Dev. 2011 Dec 15;25(24):2594-609 PMID: 22190458
  169. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Acta Neuropathol. 2010 Dec;120(6):707-18 PMID: 21088844
  170. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.
    Neuro Oncol. 2012 Nov;14 Suppl 5:v1-49 PMID: 23095881
  171. Studying a complex tumor: potential and pitfalls.
    Cancer J. 2012 Jan-Feb;18(1):107-14 PMID: 22290264
  172. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.
    Cancer Res. 2006 Apr 15;66(8):3987-91 PMID: 16618716
  173. TERT promoter mutations in primary and secondary glioblastomas.
    Acta Neuropathol. 2013 Dec;126(6):931-7 PMID: 23955565
  174. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.
    Acta Neuropathol. 2012 Sep;124(3):439-47 PMID: 22661320
  175. Genetic modeling of gliomas in mice: new tools to tackle old problems.
    Glia. 2011 Aug;59(8):1155-68 PMID: 21305617
  176. Frequency of TERT promoter mutations in human cancers.
    Nat Commun. 2013;4:2185 PMID: 23887589
  177. An in vivo patient-derived model of endogenous IDH1-mutant glioma.
    Neuro Oncol. 2012 Feb;14(2):184-91 PMID: 22166263
  178. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma.
    Cancer Cell. 2005 Aug;8(2):119-30 PMID: 16098465
  179. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas.
    Cancer Cell. 2013 Nov 11;24(5):660-72 PMID: 24183680
  180. Antagonistic modulation of gliomagenesis by Pax6 and Olig2 in PDGF-induced oligodendroglioma.
    Int J Cancer. 2012 Oct 1;131(7):E1078-87 PMID: 22514120
  181. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
    Nat Rev Clin Oncol. 2013 Jan;10(1):14-26 PMID: 23183634
  182. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
    Cancer Res. 2011 Dec 15;71(24):7587-96 PMID: 22001862
  183. Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
    Nature. 2008 Oct 23;455(7216):1061-8 PMID: 18772890
  184. Modeling Adult Gliomas Using RCAS/t-va Technology.
    Transl Oncol. 2009 May;2(2):89-95 PMID: 19412424
  185. Targeted therapy for BRAFV600E malignant astrocytoma.
    Clin Cancer Res. 2011 Dec 15;17(24):7595-604 PMID: 22038996
  186. Inhibition of BET bromodomain targets genetically diverse glioblastoma.
    Clin Cancer Res. 2013 Apr 1;19(7):1748-59 PMID: 23403638
  187. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.
    J Clin Oncol. 2008 Dec 1;26(34):5603-9 PMID: 18955445
  188. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
    Science. 2013 May 3;340(6132):622-6 PMID: 23558173
  189. Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model.
    Cancer Cell. 2009 Jun 2;15(6):514-26 PMID: 19477430
  190. Breakpoint profiling of 64 cancer genomes reveals numerous complex rearrangements spawned by homology-independent mechanisms.
    Genome Res. 2013 May;23(5):762-76 PMID: 23410887
  191. Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas.
    Neuro Oncol. 2011 Feb;13(2):212-22 PMID: 21138945
  192. Reciprocal regulation of SOCS 1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme.
    Clin Cancer Res. 2007 Apr 15;13(8):2344-53 PMID: 17438093
  193. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.
    Nature. 2012 Jan 29;482(7384):226-31 PMID: 22286061
  194. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.
    Cancer Cell. 2006 Mar;9(3):157-73 PMID: 16530701
  195. Vertebrate animal models of glioma: understanding the mechanisms and developing new therapies.
    Biochim Biophys Acta. 2013 Aug;1836(1):158-65 PMID: 23618720
  196. Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1- mutation as common tumor initiating event.
    PLoS One. 2012;7(7):e41298 PMID: 22844452
  197. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort.
    J Neurosurg. 2006 Nov;105(5 Suppl):418-24 PMID: 17328268
  198. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
    J Clin Oncol. 2009 Mar 10;27(8):1268-74 PMID: 19204207
  199. IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group.
    Childs Nerv Syst. 2011 Jan;27(1):87-94 PMID: 20725730
  200. IDH1 and IDH2 mutations in gliomas.
    N Engl J Med. 2009 Feb 19;360(8):765-73 PMID: 19228619
  201. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
    N Engl J Med. 2005 Nov 10;353(19):2012-24 PMID: 16282176
  202. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.
    Oncotarget. 2012 Jul;3(7):709-22 PMID: 22869205
  203. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.
    J Clin Oncol. 2008 Sep 1;26(25):4189-99 PMID: 18757334
  204. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
    Acta Neuropathol. 2016 Jun;131(6):803-20 PMID: 27157931
  205. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
    Clin Cancer Res. 2007 Apr 1;13(7):2038-45 PMID: 17404084
  206. Integrated genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumors.
    Nat Genet. 2002 Nov;32(3):453-8 PMID: 12355068
  207. Graded methylation in the promoter and body of the O6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells.
    J Biol Chem. 1994 Jun 24;269(25):17228-37 PMID: 8006031
  208. Evaluation status and prognostic significance of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in pediatric high grade gliomas.
    Childs Nerv Syst. 2010 Aug;26(8):1051-6 PMID: 20552207
  209. An extensive invasive intracranial human glioblastoma xenograft model: role of high level matrix metalloproteinase 9.
    Am J Pathol. 2010 Jun;176(6):3032-49 PMID: 20413683
  210. Glioblastoma models reveal the connection between adult glial progenitors and the proneural phenotype.
    PLoS One. 2011;6(5):e20041 PMID: 21625383
  211. Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma.
    Cancer Res. 2010 Mar 15;70(6):2548-57 PMID: 20197468
  212. PTEN methylation and expression in glioblastomas.
    Acta Neuropathol. 2003 Nov;106(5):479-85 PMID: 12904991
  213. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.
    Neuro Oncol. 2009 Aug;11(4):341-7 PMID: 19435942
  214. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas.
    Brain Pathol. 2013 Sep;23(5):558-64 PMID: 23414300
  215. Molecular pathogenesis of IDH mutations in gliomas.
    Brain Tumor Pathol. 2012 Jul;29(3):131-9 PMID: 22399191
  216. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group.
    Neuro Oncol. 2011 Mar;13(3):317-23 PMID: 21339192
  217. Promoter hypermethylation of the RB1 gene in glioblastomas.
    Lab Invest. 2001 Jan;81(1):77-82 PMID: 11204276
  218. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.
    Clin Cancer Res. 2005 Nov 1;11(21):7841-50 PMID: 16278407
  219. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
    N Engl J Med. 2005 Mar 10;352(10):987-96 PMID: 15758009
  220. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.
    Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6 PMID: 23530248
  221. Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease.
    Histol Histopathol. 2009 Jul;24(7):879-91 PMID: 19475534
  222. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas.
    Acta Neuropathol. 2013 May;125(5):659-69 PMID: 23417712
  223. Clonal evolution in cancer.
    Nature. 2012 Jan 18;481(7381):306-13 PMID: 22258609
Article Info
Journal
Nature reviews. Cancer
Abbr.
Nat Rev Cancer
ISSN
1474-1768
DOI
10.1038/nrc3655
Published
2014-02-00
Pages
92-107
Language
English
Region
England
NLM ID
101124168
PMCID
PMC4003223
Subset
IM
Grants
Cancer Research UK · 11736 · United Kingdom
Cancer Research UK · 13982 · United Kingdom
NCI NIH HHS · P01 CA118816 · United States
NCI NIH HHS · R01 CA169316 · United States
CIHR · Canada
External Links
PubMed source DOI: 10.1038/nrc3655 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2